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Background: The purpose of this systematic review is to assess the effectiveness of brief interventions (BIs) as part
of the Screening, Brief Intervention, and Referral to Treatment (SBIRT) model for reducing the nonmedical use of
psychoactive substances.
Methods: Bibliographic databases (including MEDLINE, Embase, The Cochrane Library, CINAHL, and PsycINFO to
April 2012) and gray literature sources were searched. We included randomized controlled trials that opportunistically
screened adolescents or adults and then provided a one-to-one, verbal BI to those at risk of substance-use harm.
Of interest was the nonmedical use of psychoactive substances (for example, drugs prohibited by international law),
excluding alcohol, nicotine, and caffeine. Interventions comprised four or fewer sessions and were compared with
no/delayed intervention or provision of information only. Studies were assessed for bias using the Cochrane risk of
bias tool. Results were synthesized narratively. Evidence was interpreted according to the GRADE framework.
Results: We identified 8,836 records. Of these, five studies met our inclusion criteria. Two studies compared BI with no
BI, and three studies compared BI with information only. Studies varied in characteristics such as substances targeted,
screening procedures, and BI administered. Outcomes were mostly reported by a single study, leading to limited or
uncertain confidence in effect estimates.
Conclusions: Insufficient evidence exists as to whether BIs, as part of SBIRT, are effective or ineffective for reducing the
use of, or harms associated with nonmedical use of, psychoactive substances when these interventions are administered
to nontreatment-seeking, screen-detected populations. Updating this review with emerging evidence will be important.
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Screening, Brief Intervention, and Referral to Treatment
(SBIRT) is a comprehensive, integrated public health ap-
proach to the delivery of early intervention and treat-
ment services for individuals experiencing substance
use-related harms, as well as those who are at risk of ex-
periencing such harms [1], who are not seeking, or un-
likely to seek treatment. The SBIRT model is based on
public health principles and procedures, and is designed to
reduce the burden of injury, disease, and disability associ-
ated with the nonmedical use of psychoactive substances.
The protocol typically begins with a screening proced-
ure that involves asking questions to evaluate whether
the individual has experienced, or is at-risk of experien-
cing, substance use-related harms. Brief interventions
(BIs) are typically delivered to those individuals at low to
moderate risk of harms. Individuals identified as experi-
encing significant harm and/or having more serious
signs of substance dependence warranting formal diag-
nosis may be referred to treatment services that are out-
side the scope of BIs.
Our interest in evaluating BIs was with respect to non-
medical use of psychoactive substances excluding alco-
hol, caffeine, or nicotine. For the purpose of this review,
nonmedical psychoactive substances are drugs prohib-
ited by international law [2], which include, but are not
limited to: amphetamine-type stimulants, cannabis, co-
caine, heroin, and MDMA (3,4-methylenedioxymetham-
phetamine); the nonmedical use of pharmaceuticals such
as benzodiazepines, opioids, or dextromethorphan; and
the use of substances such as solvents or inhalants
(for example, gasoline, acetone, etcetera) when they are
used for their intoxicating effects.
Screening
SBIRT is intended to be implemented in healthcare set-
tings or other community service settings frequented by
the general population. In order to determine the likeli-
hood that an individual is experiencing, or is at-risk of
experiencing substance use-related harms, screening
needs to be universal and opportunistic. By this, we
mean that individuals are screened upon entering a pro-
gram or organization (for example, hospital, primary
care clinic, prison, or school program) as part of a stand-
ard intake procedure or process.
Screening may be conducted in a number of different
ways. For example, intake staff may use psychometrically
validated questionnaires or instruments that have been
developed to accurately categorize users into low, mod-
erate, or high risk categories. Psychometrically validated
instruments have been developed for some types of sub-
stances, such as alcohol (Alcohol Use Disorders Identifi-
cation Test, AUDIT [3]) or cannabis (the Cannabis Use
Disorders Identification Test, CUDIT [4]). General drugscreening instruments also exists (for example, Drug
Abuse Screening Test, DAST [5]). However, screening
instruments that reliably categorize users of other sub-
stances into low or moderate risk groups have not been
developed (for example, heroin and cocaine). For those
substances, screening may simply take the form of self-
reported use or biological markers indicating use (for ex-
ample, hair, urine, oral fluid, or blood). In the absence of
validated instruments or biological markers, others may
rely on even less rigorous screening methods such as the
subjective judgment of the individual conducting the as-
sessment. Regardless of the screening method employed,
those deemed at risk of harms are typically provided a
BI or referred to treatment.Brief interventions
In addition to the variability in screening procedures
used, there is much variation in how BIs are defined and
delivered. In general, BIs are in-person, time-limited ef-
forts to provide information or advice, increase motiv-
ation to avoid substance use, or to teach behavior
change skills with the aim of reducing substance use and
the likelihood of experiencing negative consequences.
This variation includes the number of conversations or
meetings that take place during intervention delivery, as
well as the amount of time spent conducting the BI. The
systematic review conducted by Kaner et al. [6] defined
‘brief ’ to mean four or fewer sessions and, in the context
of BIs for alcohol in primary healthcare settings, are typ-
ically delivered within the normal consultation period of
5 to 30 minutes. In a review of interventions targeting
alcohol, Bien et al. [7] suggested that successful BIs typ-
ically focus on the following elements, collectively re-
ferred to using the acronym FRAMES: Feedback on
behavior and consequences, Responsibility to change,
Advice, Menu of options to bring about change, Em-
pathy, and Self-efficacy for change.
There is substantial scientific evidence of the benefits
of the SBIRT model in primary health-care settings as a
means of preventing and/or reducing the serious long-
term harms associated with excessive alcohol use [8-10].
There is also accumulating evidence suggesting that BIs
may be effective in reducing the nonmedical use of psy-
choactive substances, such as cannabis [11-15], ecstasy
[16], cocaine [12,17,18], benzodiazepines [19], and opi-
oids [3,17,20] among both youth and adults.
Although systematic reviews assessing the efficacy of
BIs in reducing harms associated with risky alcohol have
been conducted [6,21], there have been no published
systematic reviews or meta-analyses that assess the
effectiveness of BIs, among opportunistically screened
populations, as part of the SBIRT model in reducing
illicit drug use [22].
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BIs as part of the SBIRT model, compared with no BI or
provision of information only, for reducing the nonmed-
ical use of psychoactive substances among opportunistic-
ally screened populations identified as being at risk of
harms and further, to determine whether any factors
moderate the effect, using randomized evidence.
Methods
We published our methods as a protocol before conducting
the review [23] and registered the review with PROSPERO
(Registration number CRD42012002414 [http://www.crd.york.
ac.uk/PROSPERO/display_record.asp?ID=CRD42012002414]).
This review is reported according to the PRISMA statement
[24] and was conducted according to AMSTAR tool items for
additional quality control [25] [see Additional file 1].
Search strategy
We searched the following electronic databases: Ovid
MEDLINE™ In-Process & Other Non-indexed Citations
and Ovid MEDLINE™ (1946 to April 2012), Embase
Classic + Embase (1947 to 6 April 2012), The Cochrane
Library (searched 8 April 2012), Cumulative Index to
Nursing and Allied Health Literature (CINAHL™) (searched
18 April 2012), PsycINFO™ (1806 to week 1 April 2012),
Education Resources Information Center (ERIC) (searched
13 May 2012) and the CORK Database (searched 28 May
2012). All electronic search strategies were peer reviewed
using the PRESS tool prior to implementation [26]; search
strategies are presented in Additional file 2. We did not re-
strict the searches based on language, year of publication,
or publication status.
For gray literature sources, numerous websites of
relevant organizations, including those listed in ‘Grey
Matters: a practical tool for evidence-based searching’
[27], were searched between 16 May and 22 May 2012
and are listed in Additional file 2. We scanned bibliog-
raphies of included articles and relevant systematic
reviews. We searched clinicaltrials.gov and the WHO
International Clinical Trials Registry Platform for on-
going studies.
Selection criteria and process
We selected studies according to the following criteria:
Inclusion criteria:
 Study written in English or French.
 Randomized controlled trials (RCTs) or cluster RCTs.
 BIs administered to adolescents (12 to 18 years of
age or equivalent by level of schooling), young
adults (19 to 24 years of age), or adults (25 years
and older) screened at risk of harms related to
psychoactive substance use.
 Participants were identified by opportunistic
screening regardless of setting (that is, theparticipants in the study were from a screen-
detected population and not a population seeking
treatment for substance abuse). We included studies
with any screening procedure.
 Intervention was four sessions or less, included at
least one of the FRAMES elements, and was delivered
as a one-to-one verbal intervention to the individual.
 Intervention was compared with no/delayed
intervention or provision of information only.
Exclusion criteria:
 Studies assessing alcohol, nicotine, or caffeine only.
 Group interventions or text-only online
interventions.
 Studies addressing the effectiveness of the referral to
treatment component of the SBIRT model only.
We uploaded the literature search results to systematic
review software (Distiller SR©) for the study selection
process. Our search was limited to systematic reviews
published after 2009 because a recently conducted scop-
ing review [22] did not locate earlier reviews on this
topic. For all levels of study selection, we developed and
pilot tested screening questions [see Additional file 3].
All titles and abstracts of records at Level 1 were
screened once; those deemed not relevant were verified
by a second person. Full-text reports of potentially rele-
vant studies were assessed at Levels 2 and 3 by two inde-
pendent reviewers; more than one level was used due to
the complexity of applying the selection criteria to this
literature. Disagreements were resolved by consensus or
by a third reviewer. One reviewer tracked author re-
sponses regarding eligibility and identified multiple
(companion) reports of the same study at Level 4.
Data extraction and process
We extracted study and publication details, study design
characteristics, inclusion and exclusion criteria, partici-
pant characteristics, details regarding the screening
methods and personnel, details regarding the interven-
tion and comparison groups and personnel, outcomes,
and other additional information from included studies
[see Additional file 4].
We identified the following as outcomes of interest:
Primary outcomes
 Substance use
 Frequency of use
 Quantity of use
 Use-related harms or negative consequences of use
 Changes in behavior likely to result in the reduction
of negative substance use-related consequences
(positive behavior change)
 Decision to attend treatment
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 Use of different substances (including alcohol,
caffeine, nicotine) from that for which the client
received the intervention
 Intention to reduce substance use
 Other health measures
Adverse outcomes
 Any other reported adverse outcomes
These outcomes were extracted regardless of study
follow-up time. We performed data calculations where
needed (for example, change from baseline). For change-
from-baseline calculations, we assumed a correlation co-
efficient of r = 0.25.
We developed and reviewed a data collection form in
Distiller SR. One team member extracted information,
and a second person verified all information.
Risk of bias assessment
All RCTs were assessed using the Cochrane Risk of Bias
tool (RoB tool) [28]. Other sources of potential bias that
were assessed included fidelity (performance bias), re-
cruitment bias for cluster trials [29], single versus multi-
center studies [30], and study sponsorship bias. Some
bias items were assessed at the study level (for example,
randomization), while others were assessed at the out-
come level (for example, selective reporting). We contacted
corresponding authors of included studies regarding their
consent procedures to inform the assessment of participant
blinding. We assessed each study for the risk of bias for a
given outcome and then determined a summary assess-
ment across all studies for that outcome. Summary assess-
ments were categorized into low, medium, and high risk of
bias and incorporated into grading the quality of evidence.
One team member extracted risk of bias information
and a second person verified all information.
Evidence synthesis
Study characteristics were summarized narratively in the
text and presented in tables. In order to assess whether
meta-analyses of the data were possible, we assessed the
quantity and methodological and clinical homogeneity
of studies. We conducted narrative syntheses as meta-
analysis was either not appropriate or possible. Where
possible, we calculated and presented dichotomous out-
comes as risk ratios (RR) and continuous outcomes as
mean differences (MD), both with 95% confidence inter-
vals. We contacted corresponding authors regarding
inadequately reported data. Other analyses, such as sub-
group analyses and funnel plot assessment, were pre-
planned but not carried out due to few included studies.
The quality of evidence for all outcomes was evaluated
using the GRADE methodology [31]. The quality ofevidence was assessed across the domains of risk of bias,
consistency, directness, precision, and publication bias.
Each outcome was given a final adjudication of high,
moderate, low, or very low.
Protocol modifications
The pre-planned outcome ‘any standard/accepted bio-
logical markers of substance use’ represents a method
for measuring use and is captured within other listed
outcomes. Similarly, the pre-planned adverse outcome
‘self- or other reported use or increased use of different
substances’ is captured as a secondary outcome. We in-
cluded ‘composite’ outcomes where reported in studies
as they captured relevant measures (for example, the
Alcohol, Smoking and Substance Involvement Screening
Test (ASSIST)). For feasibility we used a verification
process for data extraction and risk of bias assessment
rather than dual extraction. When grading the evidence,
we felt ‘medium’ risk was more representative than ‘un-
clear’ risk for interpreting the risk of bias assessment
across domains and studies for an outcome [32].
Results
We located 9,631 bibliographic and 17 gray literature re-
cords. A flow diagram of the study selection process is
shown in Additional file 5. Of the 8,836 records that
remained after removing duplicates, 7,940 were excluded
during title and abstract screening. Of the 896 full-text
reports reviewed, 886 reports were excluded during two
rounds of full text screening. Over 50% (n = 454) of the
studies at this stage were excluded because the popula-
tion was not opportunistically screened. A further 35%
(n = 307) of the studies were excluded because they did
not meet our study design criteria (that is, RCT, or clus-
ter RCT). Remaining studies were excluded for a variety
of reasons that occurred with a frequency of 5% or less,
including full-text report was unavailable, intervention
did not meet the definition of BI, etcetera. Of the ten
remaining potentially eligible reports, eight reports de-
tailing the results of five unique RCTs were included.
Sixteen ongoing or completed trials were located [see
Additional file 6]. A list of excluded studies is reported
in Additional file 7.
Other study designs
Given only five RCTs were located, we went back to de-
termine if any excluded reports that employed other ex-
perimental designs (for example, non-RCTs, controlled
before-after (CBA) or interrupted time series (ITS)) were
relevant. Our search revealed 38 studies, but none of
those studies met remaining selection criteria. These
searches were mainly targeting RCT and non-RCT de-
signs, for feasibility of resources; however, given the few
studies meeting criteria of the 8,836 records screened,
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been missed by our search.
General characteristics of included trials
Of the five included studies, three were single-site RCTs
[17,33,34], one was a multisite RCT [12,35,36], and one
was a multisite, cluster RCT [37,38]. The single-site
studies were conducted in the United States [17,34] and
the cluster trial in Germany [37,38]. The other multisite
study was conducted in Australia, Brazil, India, and the
United States [12,35,36]. All studies were published after
2005 (Table 1). For the remainder of the review only the
main report for each included study will be cited.
Participants and setting
One of the included studies assessed the effectiveness of
BIs in homeless youth (13 to 18 years old) [33], one in
youth and young adults (14 to 21 years old) [34], one in
young adults and adults (16 to 62) [35], and two in
adults only [17,37]. Four studies took place in a health-
care setting (primary care or hospital) [17,34,35,37]
while one took place at a drop-in center [33].
Screening
There was considerable diversity in the screening instru-
ments employed in the included studies (Table 2). Only
one study [35] used a screening instrument whose psy-
chometric properties have been well established. The
other studies either used screening instruments of un-
known/questionable validity or adapted versions of in-
struments whose psychometric properties had been
published. Zahradnik et al. [37] used a combination of
two screening instruments followed with a diagnostic
interview to determine who would receive the interven-
tion [37], while Bernstein et al. [17] employed a group of
unspecified ‘substance abuse screening questions’ in con-
junction with an instrument whose validity and reliabil-
ity had been established for use in a clinical or research
setting only. The two remaining studies used investigator
developed, self-report screening instruments whose psy-
chometric properties are unknown [33,34].
Humeniuk et al. [35] was the only study to provide
BIs to those participants screened at a moderate risk
level only and then refer to treatment those screened at
high risk (as determined by the ASSIST). All other in-
cluded studies assigned participants to control or inter-
vention groups if they scored more than a specific
threshold but did not specify any upper level threshold.
Brief intervention
There was also a considerable degree of heterogeneity in
the characteristics of the BIs (see Table 3 for details
regarding the BIs and how they were administered).
Bernstein et al. [34] screened for and administered anintervention targeting a single, specific substance (canna-
bis). Bernstein et al. [17], Baer et al. [33], and Zahradnik
et al. [37] screened for and administered interventions
targeting a set of or a group of drugs: cocaine and/or
heroin [17]; alcohol, cannabis, and other drugs [33]; or
prescription drugs [37], respectively. Humeniuk et al. [35]
screened for multiple drugs then targeted the BI at the
substance that screening indicated was most problematic
or the substance of most concern to the participant [35].
In addition to targeting different substances, interven-
tions comprised diversity in the number and length of
sessions. Humeniuk et al. [35] simply assessed the effect
of a single verbal intervention and accompanying written
information [35]. The BIs in Bernstein et al. [17] and
Bernstein et al. [34] consisted of an initial verbal inter-
vention, take-home written information, and a follow-up
telephone call. Among the last two trials, Baer et al. [33]
consisted of four sessions, and Zahradnik et al. [37]
consisted of two sessions with a feedback letter mailed
eight weeks later. Despite these variations, there was
consistency in the treatment approach that informed the
BIs in that all BIs either explicitly or implicitly incorpo-
rated a motivational interviewing approach.
All trials reported using techniques/strategies to en-
sure adherence to the planned BI. Though it was implied
by all the studies that these strategies ensured that all in-
terventions were administered as planned, only one of
the included studies reported this explicitly [34].
Comparison groups
All three comparison groups of interest were encoun-
tered among included studies (Table 3). Three studies
provided participants with written information about the
risks of drug use [34,37] or list of local treatment op-
tions [17]. For the remaining two studies (no BI) Baer et
al. [33] provided the care or service sought by the indi-
vidual, and Humeniuk et al. [35] provided the care or
service plus delayed intervention.
Risk of bias assessments
Additional file 8 outlines the risk of bias assessments by
domain for included studies. Supports for judgments
are provided in Additional file 9. Overall, studies were
deemed at medium or high risk of bias for outcomes.
Most studies reported an adequately randomized method,
while two studies reported using a concealed method to
implement randomization [17,35]. We assessed ‘blinding of
participants and personnel’ across all outcomes as any sys-
tematic changes would have affected all outcomes. In all
studies, it was not possible to blind personnel to what they
were delivering to participants. In two studies, participants
were aware of the study intent and what groups they could
be allocated to; this information was unclear or likely to
have occurred in remaining studies. Outcomes collected





















BI versus no BI
Baer et al., 2007 [33];
Single site RCT;
Government funding
127 participants who were homeless and
with one or more binge drinking
episodes or used illicit drugs four or
more times in the past 30 days;
Incentives offered for enrolling and
attending BI and follow-up sessions
Those receiving alcohol or
drug treatment in the past
30 days.




Nonprofit, faith-based drop-in center 254 75 52






731 (Australia n = 171, Brazil n = 165,
India n = 177, USA n = 218) participants
aged 16 to 62 y with a fixed address
who scored in the moderate risk range
for cannabis, cocaine, amphetamine
stimulants, or opioids; Incentives offered
















One primary, urban general health
outpatient hospital setting (Brazil); 31
primary, urban, general health-care
units/clinics (Brazil, USA); one walk-in
clinic associated with a drug treatment
program (USA); several general medi-
cine and dental urban clinics (USA);
three clinics/centers specializing in sexu-
ally transmitted diseases (Australia,
Brazil).
NR 372 359
BI versus Written Information
Bernstein et al., 2009
[34]; Single site RCT;
Government funding
210 participants who reported ‘3 to
5 days per month of cannabis use were
included; Incentives offered for enrolling
and attending follow-up sessions
Those institutionalized, in
custody, in residential
treatment, receiving a rape
exam or were evaluated for
suicide precautions.





Pediatric emergency department in an
urban academic hospital.
7,804 68 71





126 participants (2 hospitals; 17
randomized wards) who consumed
opioids, anxiolytics, hypnotics and
sedatives, or caffeine with addiction
potential for more than 60 days in the
last 3 months or met criteria for DSM-IV
dependence or abuse; Incentives offered
for enrolling and attending BI and
follow-up sessions
Those using opioids for
cancer, with a terminal
disease, with dependence
on or use of illegal drugs, or
receiving substance use
treatment.
55.13 y (18 to 69
y); 64.9% versus
60%
Germany Two hospitals (general and university);
internal, surgical, and gynecological
wards
6,042 NR NR
Bernstein et al., 2005
[17]; Single-site RCT;
Government funding
1,175 participants who self-reported use
of cocaine and/or heroin in the last
30 days, and scored ≥3 on the DAST
instrument; Incentives offered for enrol-
ling and attending follow-up sessions







Three walk-in clinics (urgent care,
women’s clinic, homeless clinic) at an
urban teaching hospital
23,669 590 585
aPercent female in total randomized population; information by group not reported.



















Table 2 Description of screening procedure and instruments of included trials
Author,
year
Screening procedure Screening instrument(s) Screening criteria Validation of screening
instrument





questions about binge drinking
and past month use of illicit
drugs
One or more binge drinking
episodes or used illicit ‘street’






Questionnaires were either self-
administered (Australia, USA) or
by trained personnel (Brazil,
India) with other demographic
questions at primary care clinics
in the various sites.
The Alcohol, Smoking and
Substance Involvement
Screening Test (ASSIST V3.0 [39])
ASSIST score in the moderate
risk range (4 to 26) for cannabis,
cocaine, amphetamine
stimulants, or opioids. Those
with scores in the low and high
risk (except tobacco) ranges and
those who frequently injected
drugs were excluded.
The validity of the ASSIST has





Among participants who scored
moderate-risk for more than one
substance, the focus of the inter-
vention was the highest scoring
or the substance of most con-
cern to the participant.





instrument referred to by
authors as the ‘Youth and Young
Adult Health and Safety Needs
Survey’. Included unspecified risk
items from the USA Centers for
Disease Control, Youth
Behavioral Risk Factor
Surveillance Survey (YBRFS; [41]).
Did not report ‘at risk alcohol
use’; smoked cannabis ≥3 times
in the last 30 days; reported risky
behavior associated with
cannabis use; reported ‘3 to






Participants were asked to
complete a self-report screening
questionnaire. Those meeting




intake by asking ‘have you been
taking prescription drugs like
hypnotics, sedatives, or
analgesics regularly within the




SDS - scale’s psychometric
properties published in Gossop
et al. [42] However, psychomet-
ric properties of translated/
adapted version unknown.
1) met criteria for prescription
drug dependence or abuse (3+
points on the adapted SDS and
5+ points on the QPM and were
deemed depended via
diagnostic interview) or,
1) German translation of the
Severity of Dependence Scale
(SDS [42,43]) adapted to assess
prescription drug dependence.
2) consumed prescription drugs
with addiction potential for at
least 60 days in the last
3 months.
QPM - According to authors
the QPM was validated; how-
ever, this was impossible to
verify as results are published
in a German study [44].
2) A questionnaire for
prescription drug misuse (QPM;
[44])
Diagnostic interview. Section E of
SCID-I (Structured Clinical Inter-





NR ‘Standard substance abuse
screening questions for quantity
and frequency in the last month’
that were integrated as part of a
health needs history. Exact
questions not reported.
Current use of drugs (as
determined by the screening
questions) and ≥3 on the
10-item DAST
‘Standard substance abuse
screening questions’ - not
validated
Those screening positive were
administered the 10-item Drug
Abuse Severity Test (DAST-10
[46])
DAST-10 has satisfactory levels
of validity and reliability for use
in a clinical or research setting
[47,48]
NR, not reported; USA, United States.
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Table 3 Characteristics of brief interventions (BIs) and control groups
Author
and year
Target substance Intervention Individual
delivering BI
(training provided)
Intervention content Treatment approach Measure of
intervention fidelity
Control group














feedback on behavior and
consequences, self-efficacy for
change, and advice (with permis-
sion). Youth provided feedback
on the menu of options for dis-
cussion, and counselors ad-
dressed up to 6 topics in total
across sessions. Visuals were also
used to demonstrate risk rela-
tionships and normative
comparisons.
Authors cite Miller et al. [49]
regarding MI and the
substance use check-up
model.
Regular review of session audio
tapes by supervisor. Extent of
adherence NR.
no BI
Showers and laundry facilities,
meals, prayer, open social time,
and brief counseling and case



















































incorporated MI techniques and
was adapted culturally within
each country. The session
included feedback on behavior
and consequences and advice
and used the ASSIST Feedback
Report Card during the
discussion. Participants left
session with a copy of the
Report Card, specific drug
information booklets, and a take-
home guide (Self-help Strategies
for Cutting Down or Stopping
Substance Use)
BI designed to move
participants through
Prochaska and DiClemente’s
stages of change provided
by [50]. Interventions
incorporates FRAMES [7]
elements as well as MI
techniques [51].
Checklist of intervention details
was used to maintain
consistency across sites. Extent
of adherence NR.
no BI + Delayed intervention
Could contact the clinical
interviewer if concerns
regarding the study or their
substance use. Intervention
received after completing the




















Table 3 Characteristics of brief interventions (BIs) and control groups (Continued)



















feedback on behavior and
consequences, menu of options
to bring about change, self-
efficacy for change, and develop-
ing a behavior change plan.
Questions from the CRAFFT [52]
and a Readiness to Change ruler
were used as part of initial con-
versation. Booster call included
reviewing the change plan, in-
quiring as to progress, and of-
fered referrals.
Intervention adapted from a
previous study on adult
cocaine and heroin use by
the same author [17].
Content based MI techniques
[51,53] and previous research
[54-56].
Adherence to intervention was
assessed weekly by investigators
and the project coordinator.
Taped recordings were scored
against an adherence checklist
of key intervention elements. All
initial sessions met the required
80/100 points on the adherence
checklist.
no BI + Written Information (risks
of cannabis use, available
























of training in MI)
Verbal interventions were MI.
Specific content not described.
MI as described by Hettema




sessions were audio taped and
coded for consistency by other
researchers. Extent of adherence
NR.
no BI + Written Information
(booklet about prescription
drugs).
+ Feedback letter included








+ Throughout the intervention,
psychologists communicated the
necessity a medical professional
supervision when discontinuing
























Initial session. A semi-scripted
motivational interview tailored to
individual behavior, risks, culture
and language. Intervention in-
cluded self-efficacy for change
and an action plan for behavior
change. Participants received re-
ferrals, if desired, and written in-
formation (treatment options
and harm reduction information
about safe sex and needle
exchange).
None provided. Intervention
first developed for Project
ASSERT in the emergency
department [58] to help




role plays with simulated
patients, supervised patient
interviews, and completion of a
form per patient addressing 12
required elements. Extent of
adherence NR.
no BI + Written Information
Interventionist indicated to
participants ‘based on your
screening responses, you would
benefit from help with your
drug use’. Written information
regarding treatment options (for
example, detox, AA/NA,
acupuncture, and residential
treatment facilities) and harm
reduction information about







Telephone call. Reviewed the
action plan and addressed
alternative referrals, if needed.
aInformation provided by authors.
AA, alcoholics anonymous; ASSIST, alcohol, smoking, and substance involvement screening test; BI, brief intervention; FRAMES, feedback on behavior and consequences, Responsibility to change, Advice, Menu of
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database records) are at low-risk for assessor bias. Loss-to-
follow-up (total amount or differential amount between
groups), handling of missing data, and unknown/unre-
ported reasons were important issues regarding attrition,
and almost all studies were at unclear or high risk of bias.
Studies were also at unclear or high risk for selective
reporting bias. One study was at low risk of performance
bias regarding fidelity of the intervention (other bias), while
remaining studies were at unclear or high risk. The one
cluster trial was at unclear risk of recruitment bias. Study
sponsorship bias was not an issue in these studies.
Effects of brief interventions
The effects of BIs in the included studies are described
and analyzed based on comparison group: BI versus no
intervention and BI versus written information only. In-
cluded in the former group is the Humeniuk et al. [35]
study in which the delayed intervention was adminis-
tered after outcome data were collected at follow-up. Re-
sults of included studies are presented in Tables 4 and 5.
We were unable to fore-analyze unit of analysis errors in
studies due to insufficient information, so we report the
point estimate without confidence intervals.
Brief intervention versus no intervention
Two studies evaluated the BI with no or delayed inter-
vention. Baer et al. [33] assessed a four-session BI
targeting alcohol, cannabis, and other drug use among
adolescents at a faith-based drop-in center. Humeniuk et
al. [35] assessed a single-session intervention plus writ-
ten materials targeting cannabis, cocaine, amphetamine-
type stimulants, or opioids among those 16 years and
older at healthcare settings across four countries.
Few outcomes were reported and by only one study
each. Groups were not statistically significant for change
in frequency of use measures [33], a composite score
measure [35], and use of drop-in or other agency ser-
vices from baseline to one and/or three months of
follow-up [33] (Table 4). In Humeniuk et al. [35] general
health outcomes were only assessed among participants
in the intervention group and are therefore not included
in Table 4. Remaining outcomes of interest were not
assessed in either study.
Brief intervention versus written information only
Three studies evaluated the BI compared with the
provision of written information only about the risks of
drug use or local treatment services/options. Bernstein
et al. [34] assessed one session plus written information
and a telephone call targeting adolescents and young
adults cannabis use at a pediatric emergency hospital de-
partment. Zahradnik et al. [37] assessed one session plus
telephone call and a feedback letter targeting those 18and older who regularly use prescription drugs with
addiction potential or met DSM-IV criteria for depend-
ence in a hospital setting. Finally, Bernstein et al. [17]
assessed one session plus written information and a tele-
phone call targeting those 18 years and older reporting
heroin or cocaine use.
Most outcomes of interest were reported on but
mainly by one study each. Some outcomes were assessed
with multiple measures. Where authors reported two or
more substances together, data for the individual sub-
stances are provided in Additional file 10. A few studies
addressed abstinence as a measure of substance use for
differing substances and with varied follow-up times: Two
studies were not statistically significant at 3-months
[34,37], one study not significant at 6 months [17], and
two studies reported mixed results at 12-months [34,37]
(Table 5). With few studies and important clinical and
methodological heterogeneity between those studies, we
did not meta-analyze. Remaining outcome measures
(other substance use measures, frequency of use, quantity
of use, use-related harms, positive behavior change, other
health measures) were mostly not statistically significant
[17,34,37] (Table 5, Additional file 10). A few measures
(quantity of use, decision to attend treatment, and use of
different substances) were poorly reported (Table 5).
‘Intention to reduce use’ was not reported in any study.Discussion
Few studies have assessed the effectiveness of BIs among
opportunistically screened populations as part of the
SBIRT model for reducing the nonmedical use of psy-
choactive substances. When comparing the intervention
with no intervention or to written information only,
most outcomes were not statistically significant. How-
ever, the overall quality of the evidence per outcome is
limited or very uncertain [see Additional file 11]. Due to
the few included studies, results are imprecise and
largely could not be assessed for consistency. The litera-
ture has important methodologic limitations leading to
medium or high risks of bias for outcomes. The body of
evidence, therefore, is limited given the few included
studies with mainly small sample sizes and the hetero-
geneity in study characteristics, including the measure-
ment of outcomes.Practice implications
Insufficient evidence exists to make conclusions as to
whether BIs are effective or ineffective at reducing the
use of or harms associated with the nonmedical use of
psychoactive substances other than alcohol, nicotine, or
caffeine when these interventions are administered to
nontreatment-seeking, screen-detected populations.














Not reported in any studies n/a n/a Not estimable 0 (0) n/a
Frequency of use
Change in days of use - Cannabis 1 mo -3.7 versus -6.1 d (fewer d at 1 mo) MD 2.40 (-3.80 to 8.61)c 1 (89) Very Low (+) value for MD means fewer days of use with control
Self-report, past 30 d
Change in mean from baselineb [33] 3 mo -2.6 versus -5.9 d (fewer d at 3 mo) MD 3.30 (-2.84 to 9.44)c 1 (89) Very Low
Change in days of use - Other drugsd 1 mo -2.3 versus -3 d (fewer d at 1 mo) MD 0.70 (-2.95 to 4.35)c 1 (89) Very Low
Self-report, past 30 d. 3 mo -2.8 versus -2.3 d (fewer d at 3 mo) MD -0.50 (-4.30 to 3.30)c 1 (89) Very Low
Change in mean from baselineb [33]
Change in days abstinente 1 mo 3.7 versus 6.4 d (more d at 1 mo) MD -2.70 (-8.21 to 2.81)c 1 (89) Very Low (-) value for MD means more days abstinent with control
Self-report, past 30 d.
Change in mean from baselineb [33] 3 mo 2.7 versus 6 d (more d at 3 mo) MD -3.30 (-8.73 to 2.13)c 1 (89) Very Low
Quantity of use
Not reported in any studies n/a n/a Not estimable 0 (0) n/a
User-related harms or negative consequences of use
Not reported in any studies n/a n/a Not estimable 0 (0) n/a
Positive behavior change
Not reported in any studies n/a n/a Not estimable 0 (0) n/a
Decision to attend treatment
Not reported in any studies n/a n/a Not estimable 0 (0) n/a
Composite outcome
ASSIST Tool Scoref - All substances 3 mo -7.8 versus -4.6 (fewer points at 3 mo) MD -3.20, 95% CI
(-6.77 to 0.37)
1 (628) Low Higher score = higher substance involvement.
Sum score, range 0 to 27+ points. (-) value for MD means greater reduction in
change score with BI
Change in means from baselineb [35]
SECONDARY OUTCOMES
Use of different substances
Not reported in any studies n/a n/a Not estimable 0 (0) n/a
Intention to reduce use




















Table 4 Evidence table for brief intervention (BI) versus no BI in participants screened for at-risk substance use (Continued)
Use of drop-in centre services 1 mo 0.9 versus -0.2 d (more versus fewer d) MD 1.10 (-1.88 to 4.08)cg 1 (89) Very Low (+) value for MD means greater use with BI
Objective, past 30 d.
Change in means from baselineb [33] 3 mo −1.1 versus -1 d (fewer d at 3 mo) MD -0.10 (-3.23 to 3.03)cg 1 (89) Very Low
Use of drop-in additional services 1 mo 0 versus 0.1 d (more d at 1 mo) MD -0.10 (-0.72 to 0.52)cg 1 (89) Very Low
Objective, past 30 d.
Change in means from baselineb [33] 3 mo 0.5 versus -0.1 d (more versus fewer d) MD 0.60 (-0.15 to 1.35)cg 1 (89) Very Low
Use of other agency services 1 mo −2.4 versus -7 d (fewer d at 1 mo) MD 4.60 (-5.05 to 14.25)cg 1 (89) Very Low
Self-report, past 30 d.
Change in means from baselineb [33] 3 mo −3.4 versus -8.2 d (fewer d at 3 mo) MD 4.80 (-4.44 to 14.04)cg 1 (89) Very Low
ADVERSE OUTCOMES
Not reported in any studies n/a n/a Not estimable 0 (0) n/a
aFor change from baseline data, means for baseline and follow-up timepoints are shown in Table S5, where possible.
bChange in mean analysis calculated as the reported mean at follow-up minus the mean at baseline.
cCalculated from authors’ data at baseline and follow-up, assuming a correlation coefficient of 0.25.
dDrugs other than tobacco, alcohol, cannabis were assessed.
eA few people with alcohol use were included in this analysis.
fComposite outcome: substance use, frequency of use, use-related harms or negatives consequences, intention to reduce substance use, another person concerned with use, use of drug by injection.
gPossible unit of analysis error.


































Abstinence - All substances 3 mo Range 14 to




2 (223) Very low Two studies not statistically
significant.
RR 2.08c
Cannabis (Self-reportb, past 30 d, [34]). See Comments
Sedatives/hypnotics/opioidsd
(NR, period not provided, [37])
Abstinence - Cocaine/heroin 6 mo 17% versus 13%f Adj RR 1.41
(0.98 to 1.95)gh
1 (778) Low
Objectivee, past 30d [17]





2 (228) Very low Mixed results between studies.
Adj RR 1.30cgiCannabis (Self-reportb, past 30d, [34])
See CommentsSedatives/hypnotics/opioidsd
(NR, assessment period NR, [37])






Self-reportb, past 30d [34]





1 (102) Very low
Reducing use >25% - Sedatives/hyp-
notics/opioidsd
3 mo 29/56 (52%)
versus 21/70
(30%)
RR 1.73c 1 (126) Very low Results favor BI over control.
NR, period of assessment not provided
[37]
12 mo 28/56 (50%)
versus 34/70
(49%)f
Adj RR 0.96cgi 1 (126) Very low Results NS
Frequency of use
Change in cannabis consumption.
Mean change from baselinek, self-reportb,
past 30 d [34]
3 mo -5 versus -0.8 d




1 (95) Low (−) value for MD indicates fewer
d consumption with BI
12 mo -7.1 versus -1.8






Defined daily dosage - Sedatives/hyp-
notics/opioidsd
3 mo 0.42 versus 0.12
(dosage higher
at 3 mo)
MD 0.30c 1 (126) Very low Results NS
Mean change from baselinek, NR
Patient’s dose of a given prescription
drug per day (in mg) divided by the
product-specific WHO measure [37]
12 mo Not provided See Comment 1 (126) Very low Authors state no significant
difference between
groups, P = 0.330
Change in drug level - Cocaine 6 mo -180 versus
-21 ng/ 10 mg
(less at 6 mo)
See Comment 1 (376) Low Authors state adjusted P = 0.058,
likely representing multiple
adjusted analysesmChange in mean from baseline
l,
objectivee [17]
Change in drug level - Opioids 6 mo -7.6 versus
-7.8 ng/ 10 mg
(less at 6 mo)
See Comment 1 (189) Low Authors state adjusted P = 0.186,
likely representing multiple
adjusted analysesmChange in mean from baseline
l,
objectivee [17]
Use-related harms or negative consequences of use
Carried a weapon (gun, knife, club) 3 mo 1 (97) Very Low
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Self-report, past 30 d [34]





1 (102) Very Low
Drove a car after using cannabis.
Self-report, past 30 d [34]
















Rode in a car with a person
drunk/high after cannabis use.
Self-report, past 30 d [34]





1 (97) Very Low





1 (102) Very Low





1 (97) Very Low







Tried to cut back on cannabis use.
Self-report, past 3 and 12 mo [34]






12 mo 34/47 (72%)
versus 33/55
(60%)f
Adj RR 0.96 (0.91
to 1.45)gn
1 (102) Low
Tried to stop using cannabis.
Self-report, past 3 and 12 mo [34]












‘Tried to be careful about situations
you got into when using marijuana’












Decision to attend treatment
Abstinence obtained by substance
use treatment, including detox [17]
6 mo n/a Not estimable 1 (118) n/a Data poorly reported, not
provided by group.
SECONDARY OUTCOMES
Use of different substances
Change in type of drug from baseline
to follow-up - Cocaine/opioids
6 mo n/a Not estimable 1 (118) n/a Poorly reported by authors.
Change from baseline [17]
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Table 5 Evidence table for brief intervention (BI) versus written information in participants screened for at-risk
substance use (Continued)
Intention to reduce use
Not reported in any studies n/a n/a Not estimable 0 (0) n/a
Other health measures






Self-report, past 30 d [34]






Change in ASI composite score from
baseline - Cocaine and/or heroin
3 mo Not reported Not estimable;
See Comment
1 (854) Low Authors state not
statistically significant







1 (562) Low Authors state P = 0.06








1 (562) Low Authors state P = 0.055
Other adverse outcomes
Not reported in any studies n/a Not estimable 0 (0) n/a
aFor change from baseline data, means for baseline and follow-up timepoints are shown in Table S5, where possible.
bSelf-report using Timeline Followback Calendar.
cConfidence interval not presented due to unit of analysis error.
dA small proportion (1.5%) of participants were assessed for caffeine use in this study.
eObjective measure by biochemical hair analysis.
fUnadjusted event rates.
gAdjusted RR calculated from authors’ adjusted OR.
hAdjusted for health insurance and homelessness.
iAdjusted for prescription drug dependence according to the Structured Clinical Interview for DSM-IV Axis I disorders.
jUnclear what variables were adjusted for.
kMean change analysis first calculates the change between follow-up and baseline values for each participant and then computes the mean across those data.
lChange in mean analysis calculated the reported mean at follow-up minus the mean at baseline.
mUnclear but likely adjusts for gender, race, age, EuroQol scores, previous psychiatric history, randomization status, education level, drug route, drug problem
severity (Drug Abuse Severity Test score at baseline, polydrug use, injection drug use, baseline Addiction Severity Index drug score, number of previous treatment
episodes) and readiness to change.
nUnclear what variables adjusted for. adj, adjusted; ASI, addiction severity index; BI, brief intervention; CI, confidence interval; d, days; info, information; med,
medical; MD, mean difference; mo, months; NS, not significant; RR, risk ratio.
Young et al. Systematic Reviews 2014, 3:50 Page 15 of 18
http://www.systematicreviewsjournal.com/content/3/1/50Research implications
We are aware of 16 ongoing studies, some with large
sample sizes, which are potentially relevant to this re-
view. Since the current evidence base is inconclusive,
updating this review when the results of the ongoing
studies become available will be important.
Given the variation observed among characteristics of
the included studies, future research in the area would
benefit from modifications in scope and study design.
Firstly, we propose a focus on primary care settings, to
supplement the evidence base of four of our included
studies, before evaluating other community service set-
tings. Secondly, a standard, validated screening instru-
ment with an acceptable sensitivity and specificity
profile is an important first step in determining the ef-
fectiveness of the SBIRT model among nontreatment-
seeking populations. The instrument should be designed
to take a relatively short time to complete, as a prag-
matic consideration for implementing the SBIRT model.
Thirdly, interventions that are more clearly reported andwith sufficient detail to be replicated in other trials
would also help develop this body of evidence. Fidelity
of the delivered intervention should be collected and re-
ported on. Finally, agreement on a core set of defined
outcomes, their measurements, and lengths of follow-up
will be essential to ensuring relevance to practice and to
allow meta-analysis of studies.
There are additional items that researchers could im-
plement to increase internal validity. The consent
process should be designed such that participants are
unaware of the intent of the study or to the groups for
which allocation is possible. Researchers should consider
using a sham intervention as a control group that would
address another aspect of wellbeing (for example, nutri-
tion) to help blind participants to group allocation. In
addition, if known, researchers should indicate reasons
for client drop-out.
Incomplete reporting (for example, informed consent
procedures and intervention details) was a general bar-
rier in attempting to assess studies against inclusion
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et al. [59] provides detailed reporting guidance.
Future research incorporating these modifications will
enable meaningful statements on SBIRT effectiveness.
Consult the protocol modifications section for possible
limitations; our work has been conducted according to
AMSTAR standards.
Conclusions
Insufficient evidence exists as to whether BIs as part of
SBIRT are effective or ineffective at reducing the use of or
harms associated with the use of nonmedical use of psy-
choactive substances other than alcohol, nicotine, or
caffeine when these interventions are administered to
nontreatment-seeking, screen-detected populations. Given
the evidence base is inconclusive, emerging evidence from
existing ongoing studies may help to stabilize conclusions
about the effectiveness of BI.
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